key: cord-0284893-2nqtr0nd
authors: Zhang, Y.; Liu, X.; Lin, M.; Zan, J.; Hu, Y.; Wang, X.; Wu, W.; Zhou, T.; Zhang, H.; Lv, J.; Yang, L.; Zhang, Z.
title: Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients
date: 2022-01-14
journal: nan
DOI: 10.1101/2022.01.14.22269182
sha: 98cb95d6f1fe1ea90760a3382db151798e37a823
doc_id: 284893
cord_uid: 2nqtr0nd

Patients with chronic kidney disease (CKD) are at higher risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality. However, a significant portion of CKD patients showed hesitation toward vaccination in telephone survey of our center. Yet no serial data available on humoral response in patients with CKD, especially those on immunosuppression. We conducted a pilot, prospective study to survey the safety and humoral response to inactivated SARS-CoV-2 vaccine in CKD patients receiving a 2-dose immunization of inactivated SARS-CoV-2 vaccine. We found the neutralizing antibody titers in CKD patients was significantly lower than that in healthy controls, hypertension patients, and diabetes patients. Notably, immunosuppressive medication rather than eGFR levels or disease types showed effect on the reduction of immunogenicity. Interestingly, a third dose significantly boosted neutralizing antibody in CKD patients while immunosuppressants impeded the boosting effects. In conclusion, our data demonstrates that CKD patients, even for those on immunosuppression treatment, can benefit from a third vaccination boost by improving their humoral immunity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Patients with chronic kidney disease (CKD) are at higher risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality. However, a significant portion of CKD patients showed hesitation toward vaccination in telephone survey of our center.

Yet no serial data available on humoral response in patients with CKD, especially those on immunosuppression. We conducted a pilot, prospective study to survey the safety and humoral response to inactivated SARS-CoV-2 vaccine in CKD patients receiving a 2-dose immunization of inactivated SARS-CoV-2 vaccine. We found the neutralizing antibody titers in CKD patients was significantly lower than that in healthy controls, hypertension patients, and diabetes patients. Notably, immunosuppressive medication rather than eGFR levels or disease types showed effect on the reduction of immunogenicity. Interestingly, a third dose significantly boosted neutralizing antibody in CKD patients while immunosuppressants impeded the boosting effects. In conclusion, our data demonstrates that CKD patients, even for those on immunosuppression treatment, can benefit from a third vaccination boost by improving their humoral immunity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint Patients with chronic kidney disease (CKD) are at higher risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality than general populations and, early vaccination should be prioritized for this vulnerable population. However, concerning safety and efficacy, a significant portion of CKD patients (1720/2509, 68.6%) showed hesitation toward vaccination in telephone survey of our center (Supplementary received both sequentially. The most common form of CKD was chronic glomerulonephritis (27/45, 60.0%) followed by podocytopathy (5/45, 11.1%) and metabolic kidney disease (5/45, 11.1%). There were 18 patients taking immunosuppressants during the vaccination period with 17 (94.4%) receiving monotherapy. We tightly controlled age, female ratio, types of administered vaccines and sampling time across groups, except that the average age of diabetes patients is significantly older than CKD patients. None of these participants reported severe adverse effects after vaccination.

Using neutralizing antibody titer of 2 as seroconversion cutoff, we found 84% (38 of 45) of CKD patients seropositive, which was lower than that in healthy controls (98%), hypertension patients (98%) and diabetes patients (95%). The median neutralizing antibody titers in CKD patients was 6.29 (IQR, 2.78-14.62), which was significantly lower than that in healthy controls [8.91 (IQR, 6.14-16.01), P = is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint observe SARS-CoV-2-specific IgG or IgM differences between CKD patients and controls (Figure 1 b-c) , despite of strong association between neutralizing antibody and SARS-CoV-2-specific IgG levels (Supplementary Figure 3) . To better understand the immunogenicity of inactivated SARS-CoV-2 vaccine in CKD patients, we further stratified CKD patients into subgroups according to their disease diagnosis, eGFR levels and medication status (receiving immunosuppressants or not). Notably, immunosuppressive medication (Figure 1d ) rather than eGFR levels (Figure 1e Our initial analysis showed that majority (84%) of CKD patients acquired detectable neutralizing antibody against SARS-CoV-2 without severe adverse effects, while the antibody titers were lower than controls. In contrast, we did not observe such difference in SARS-CoV-2-specific IgG or IgM. The deviance between neutralizing antibody and SARS-CoV-2-specific IgG responses in CKD patients indicates that neutralizing antibody rather than IgG might be the most important marker reflecting humoral immune response in CKD patients. Subgroup analyses showed that immunosuppressive therapies rather than eGFR levels or disease diagnosis impair SARS-CoV-2 vaccine-induced immunity. Our analysis in non-dialysis kidney disease patients greatly supplemented previous studies on immunosuppressive therapies 4,5 and dialysis 6,7 impaired vaccine responses. We found that taking immunosuppressants hampers neutralizing antibody response in CKD patients and sensitizes neutralizing antibody response to kidney function. Additionally, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint our data demonstrates that CKD patients, even for those on immunosuppression treatment, can benefit from a third vaccination boost by improving their humoral immunity.

The authors thank the study participants, and clinical staff and nurses who providing help for their participation and sampling. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint

Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study

Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients

Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis

Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report

It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.14.22269182 doi: medRxiv preprint